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Formulary Changes for Insulin Products
Hospitalized patients who have
hyperglycemia either have preexisting diabetes, have undiagnosed diabetes, or have hyperglycemia due to factors associated with hospitalization (eg,
medications, stress, surgery).
Epidemiological studies and data
from clinical trials suggest that,
regardless of the diagnosis of
diabetes, hyperglycemia during
hospitalization is associated with
increased morbidity and mortality. However, control of the patient’s blood glucose in the hospital has not been a therapeutic
priority until the last few
years.1,2
In 2004, the Medical Center introduced the Diabetes Management Service (DMS) as part of a
hospital initiative to offer specialized care to patients with diabetes or problems with hyperglycemia. Since that time, DMS
has developed numerous tools to
improved care of these patients,
including revised insulin order
forms, adult hypoglycemia protocol, and clinical pathways to
aid nurses. With the advent of
these practice changes, issues
with insulin products still arise.
Insulin is frequently reported to
be associated with significant

risk when used inappropriately,
making it a commonly recognized
high-alert medication.4-6 From
2003 to 2005, insulin products
ranked second at MUSC among
the list of most frequently reported
agents with medication occurrences.4 Currently, the goal is to
minimize medication misadventures associated with insulin products and standardized treatment of
patients with hyperglycemia.
DMS recommends that patients
receive a long-acting insulin (ie,
Novolin® NPH or insulin glargine
[Lantus®]) as a basal insulin with
a rapid-acting insulin (ie, insulin
aspart [Novolog]) for meal coverage. Correction insulin can be
added to the rapid-acting insulin if
hyperglycemia occurs despite the
scheduled insulin regimens. The
correction protocols replace the
sliding scale protocols.
Due to these recommendations,
the formulary status of selected
insulin
products
has
been
changed. The rationale is to ensure safe use of insulin. The goal
is to decrease the number of insulin products in order to decrease
the opportunity for error. The use
of regular insulin for subcutaneous dosing will be restricted to
practitioners from DMS. This
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product will still be available for
the following intravenous uses:
continuous infusions, parenteral
nutrition, hyperkalemia, insulin
pumps, pediatric dilutions, and
deceased organ donors. Insulin
aspart (NovoLog®) will be the insulin of choice for meal coverage
and correction. Other changes
include the deletion of NovoLIN®
70/30 and the addition of NovoLOG® Mix 70/30. Both NovoLOG® and NovoLOG® Mix 70/30
are 1:1 conversions with regular
insulin and NovoLIN 70/30, respectively.
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Figure 1. Educational Poster for Formulary Insulin Changes

The formulary effective date of
these change is July 1, 2006.
DMS has provided education regarding these changes to all of the
departments and educational posters have been posted in patient
care areas (Figure 1).

Enhancements to the
Online MUSC-MC
Formulary of
Accepted Drugs
The MUSC-MC Formulary of
Accepted Drugs is a list of medications that are approved for
use at the Medical Center. The
goal of the of the formulary is
to provide the most safe, efficacious, and cost-effective treatment
to our patients.
The formulary is available at
www.formluaryproductions.com/
musc, and the link can be found
on the MUHA Intranet Page. The
online formulary contains medications and respective formulations
that are approved for use at the
Medical Center, comments regarding restrictions, links to medication-specific preprinted order

forms, and links to the Micromedex monograph, patient education leaflet, and PubMed citations for each medication. The
online formulary may also be
downloaded to a PDA through
AdvantGo. To download the
formulary, follow the instructions provided on the Web site.
Recently, the main page of the
Web site has been updated to
provide access to relevant information regarding medication use

(Figure 2). Additions include
links to the Pharmacy and Therapeutics Update: Drug Information
for Health Care Professionals
newsletters, Automatic Therapeutic Substitution Protocols, Formulary Restricted Medications, Drug
Information Resources, Medication Safety Resources, Drug
Shortage Resources, and Useful
Healthcare Internet Sites.
The Drug Information Resources
section provides links to the adult
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and pediatric continuous infusion
guidelines, adult and pediatric intravenous push medication administration charts, adult and pediatric electrolyte guidelines, and
other guidelines and charts pertinent to medication use. In addition, this section provids a link to
the Medicare Part D and Medicaid
formularies.
The Medication Safety section
provides links to the 2006 National Patient Safety Goals,
MUSC looks-alike, sounds-alike
medications, medications with
black-box warnings, oral formulations that should not but crushed
or chewed, and the order writing
guidelines with prohibited abbreviations.
The Drug Shortage Resource section provided links to the MUSC
drug shortage Web site and information available through the Food
and Drug Administration (FDA)
and the American Society of
HealthSystem Pharmacists.
Useful healthcare internet sites
have been compiled to assist
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healthcare professionals with
information for themselves and
their patients. The sites for
healthcare professionals include
the FDA, Centers for Disease
Control and Prevention (CDC),
eMedicine, MDConsult, Medscape, MerckMedicus, National
Guideline Clearinghouse, National Library of Medicine, and
UpToDate.
For consumers,
eMedicine - Consumer Edition,
KidsHealth, and MedlinePlus
provide information regarding
disease states and medications.
For any questions regarding this
site, please contact the Drug Information Center at 2-3896 or
druginfo@musc.edu.

These changes were necessary to
place first-line medications
needed for any mayday in the
OTBs, and to allow the eventual
removal of the “Anaphylaxis
Kits” from the floors. The effective date is August 31, 2006; however, specific notification will be
sent when this occurs.
The updated OTBs will have
dated blue labels (July 5, 2006) on
the boxes identifying the additions
and deletions, as well as revised
content lists and patient charge
sheets. As the current OTBs are
returned to the Distribution Center, they will be exchanged with
the refurbished, updated boxes.

Changes for the
Mayday Orange
Tackle Boxes

Any questions about the changes
or use of the safety shield needles
should be referred to Donna Barrio, PharmD, Coordinator, Pharmacy Support Services, at 2-1363
or barriodj@musc.edu.

After a recent review by the
Mayday Committee, the orange
tackle boxes (OTBs) will undergo changes to certain products and medications (See Tables 1 and 2).

Other information regarding maydays can be found at
www.mcintranet.musc.edu/
mayday/.

Figure 2. MUSC-MC Formulary Of Accepted Drugs Web site

Did You Know...
The Human Papillomavirus
(HPV) Virus Vaccine (Gardasil®),
manufactured by Merck, is the
first vaccine developed to prevent
cervical cancer, precancerous
genital lesions and genital warts
due to HPV. The vaccine is
highly effective against 4 types of
the HPV virus, including 2 that
cause about 70% of cervical cancer. Those who have not acquired
HPV would get the full benefits of
the vaccine.
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CDC Advisory Committee on Immunization Practices (ACIP) recommends that the HPV vaccine be
routinely administered to all girls
when they are between 11 and 12
years of age. Additionally, the
ACIP recommendation allows for
the vaccination of girls beginning
at 9 years old as well as vaccination of girls and women between
13 and 26 years of age. The vaccine should be administered before onset of sexual activity (ie,
before women are exposed to the
viruses), but females who are
sexually active should still be vaccinated.
FDA has approved the first generic version of Zoloft tablets
(sertraline), as well as a liquid
concentrate (sertraline hydrochlo-
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ride). Sertraline is indicated for
the treatment of major depressive disorder (MDD) in adults
and anxiety-related disorders.
FDA has completed the safety
assessments of telithromycin
(Ketek®), which is indicated for
the treatment of acute exacerbation of chronic bronchitis, acute
bacterial sinusitis, and community acquired pneumonia.
Telithromycin has been associated with rare cases of serious
liver injury and liver failure with
4 reported deaths and 1 liver
transplant. FDA determined that
additional warnings are required
within the product labeling.
Physicians and patients are encouraged to be aware of signs
and symptoms of liver problems.

Table 1. Items Removed from the Orange Tackle Boxes
Items Removed
Quantity
Epinephrine 1-mL ampule (1 mg/mL)
2
Lidocaine 2% 100-mg/5-mL syringe
1
21 g 1-inch ‘plain’ needles
12
TB syringes with ‘plain’ needles
5
Epinephrine 1-mg/mL vial label that reads
“FOR HIGH DOSE EPI ONLY”
Table 2. Items Added to the Orange Tackle Boxes
Items Added

The Pharmacy and Therapeutics
Committee recently approved the
following actions:
Additions:
Effective June 19, 2006
Vytorin®
10/10-, 10/20-, 10/40-, and
10/80-mg tablets
Effective July 1, 2006
NovoLog® Mix 70/30
100-units/10-mL vials
Addition with Restriction:
Effective June 19, 2006
Cetuximab (Erbitux®)
100-mg/50-mL single-use vials
Restriction Added:
Effective July 1, 2006
As part of the initiative to limit the
use of regular insulin (Novolin®
R), the subcutaneous administration of this product will be restricted to the Diabetes Management Service.
100-units/10-mL vials

--

Quantity

Adenosine 6-mg/5-mL syringe

3

Amiodarone 150-mg/3-mL vial

2

Diphenhydramine 50-mg/mL (1-mL) vial

1

Methylprednisolone sodium succinate
500-mg vial
21 g 1-inch Safety Shield (eclipse) needles

1

TB syringe with Safety Glide needles

5

Epinephrine 30-mL vials (1 mg/mL) label that
reads “FOR SC OR ET USE ONLY”
Amiodarone dilution instruction sheet with
5% dextrose solution (50 mL) and 30-mL syringe
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8

---

Line Extensions:
Effective June 19, 2006
Sarna® Lotion
7.5-oz bottles
Albuterol/ipratropium (DuoNeb®)
3-mL unit-dose vials
Deletions:
Effective June 19, 2006
Rabies vaccine (RabAvert®)
1-mL injection
Effective July 1, 2006
Novolin® 70/30
100-units/10-mL vials

